“We are convinced that the time has now come for the successful development of effective treatments against Alzheimer’s. Great strides have been made in diagnostics and clinical research in recent years that have led to an increased understanding of this serious disease. “Johan Sandin, CEO AlzeCure AB (publ)
Financial information for the fourth quarter 2018
- Net sales during the period amounted to SEK 0 thousand (0).
- Earnings after financial items amounted to SEK -12,967 thousand (-5,672).
- Earnings per share before and after dilution amounted to SEK -0.42 (-0.30).
- Cash and cash equivalents amounted to SEK 234,549 thousand (53,952) as of 12/31/2018.
Financial information for the full year, 2018
- Net sales during the period amounted to SEK 0 thousand (0).
- Earnings after financial items amounted to SEK -35,985 thousand (-10,822).
- Earnings per share before and after dilution amounted to SEK -1.58 (-0.79)
- The Board proposes that no dividend be paid for the financial year.
Significant events during the period January to December 2018
October – December
- An extraordinary shareholders’ meeting was held on October 15. The meeting resolved to issue a stock dividend, change the incorporation form to public and elect Pirkko Sulila Tamsen as a member of the board. Pirkko has many years’ experience from development companies in the pharmaceutical sector as well as research, entrepreneurship and management in knowledge-based enterprises.
- The Board resolved to list the company’s shares on Nasdaq First North Premier, which took place on November 28.
- The company was granted the necessary public authority approvals to begin clinical phase 1 trials for the ACD855 drug candidate in the NeuroRestore platform. The company dosed the first subjects in the study in December.
January to September
- During the summer, the company carried out a targeted new share issue, raising proceeds of around SEK 40 million.
- Ellen Donnelly was elected to the board at the AGM on May 16, further reinforcing and broadening board expertise.
- Preclinical testing of ACD855 was concluded in July.
Significant events after the closing date
No significant events have taken place since the closing date.
Read the full year-end report at: https://www.alzecurepharma.se/en/section/investors/financial-reports/
For further information, please contact:
Johan Sandin, CEO of AlzeCure
email: johan.sandin@alzecurepharma.com
This information was made available through the offices of the above contact for publication on February 28 at 8.00 CET.
AlzeCure in brief
AlzeCure Pharma AB (publ) is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease. The company is listed on Nasdaq First North Premier and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptomatic drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease. For more information, please visit www.alzecurepharma.se.
FNCA Sweden AB is the company’s Certified Adviser.
FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se.